# EDGAR Filing Document

**Accession Number:** 0001648257
**File Stem:** 0001648257-23-000015
**Filing Date:** 2023-3
**Character Count:** 14387
**Document Hash:** f35afc21939eb8569c1f1ebf0232d7c7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001648257-23-000015.hdr.sgml**: 20230306

**ACCESSION NUMBER**: 0001648257-23-000015

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20230306

**FILED AS OF DATE**: 20230306

**DATE AS OF CHANGE**: 20230306

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** HUTCHMED (China) Ltd
- **CENTRAL INDEX KEY:** 0001648257
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** E9

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37710
- **FILM NUMBER:** 23707416

**BUSINESS ADDRESS:**
- **STREET 1:** 48TH FLOOR, CHEUNG KONG CENTER
- **STREET 2:** 2 QUEEN'S ROAD CENTRAL
- **CITY:** HONG KONG
- **STATE:** K3
- **ZIP:** 00000
- **BUSINESS PHONE:** 852-2121-3888

**MAIL ADDRESS:**
- **STREET 1:** 48TH FLOOR, CHEUNG KONG CENTER
- **STREET 2:** 2 QUEEN'S ROAD CENTRAL
- **CITY:** HONG KONG
- **STATE:** K3
- **ZIP:** 00000

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Hutchison China MediTech Ltd
- **DATE OF NAME CHANGE:** 20150716

------

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

------

**FORM 6-K**

------

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13A-16 OR 15D-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the Month of March 2023**

**Commission File Number: 001-37710**

------

**HUTCHMED (CHINA) LIMITED**

(Translation of registrant's name into English)

------

**48th Floor, Cheung Kong Center, 2 Queen's Road Central, Hong Kong**

(Address of principal executive offices)

------

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ⌧ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F ◻

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ◻

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ◻

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

------

**HUTCHMED (CHINA) LIMITED**

**Form 6-K**

<u>EXHIBIT INDEX</u>

---

| | | |
|:---|:---|:---|
| **Exhibit No.** |  | **Description** |
| Exhibit 99.1 |  | Announcement relating to vesting of awards under the Long Term Incentive Plan |

---

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| HUTCHMED (CHINA) LIMITED | HUTCHMED (CHINA) LIMITED |
| By: | /s/ Johnny Cheng |
| Name: | Johnny Cheng |
| Title: | Chief Financial Officer |

---

Date: March 6, 2023

------

## Exhibit 99.1

**Exhibit 99.1**

![Graphic](hcm-20230306xex99d1001.jpg)

**Vesting of awards under the Long Term Incentive Plan**

**Hong Kong, Shanghai & Florham Park, NJ — Monday, March 6, 2023:** HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) announces that following the announcement of the 2022 annual results of HUTCHMED on February 28, 2023, the following awards granted under the Long Term Incentive Plan ("LTIP") on April 20, 2020 to Dr Weiguo Su and Mr Johnny Cheng were vested on March 3, 2023:-

---

| | |
|:---|:---|
| &nbsp;&nbsp;<u>Award Holders</u> | &nbsp;&nbsp;<u>Number of American depositary shares ("ADS")</u> |
| &nbsp;&nbsp;**Person Discharging Managerial Responsibilities** |  |
| &nbsp;&nbsp;Dr Weiguo Su (Executive Director, Chief Executive Officer and Chief Scientific Officer) | &nbsp;&nbsp;50431 |
| &nbsp;&nbsp;Mr Johnny Cheng (Executive Director and Chief Financial Officer) | &nbsp;&nbsp;22953<br>|
| &nbsp;&nbsp;**Total** | &nbsp;&nbsp;73384 |

---

The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.

------

&nbsp;&nbsp;&nbsp;&nbsp;**(a)** **Dr Weiguo Su** 

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**1**  | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated**  | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated**  | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated**  |
| &nbsp;&nbsp;<br>a) | &nbsp;&nbsp;<br>Name<br>| &nbsp;&nbsp;<br>Dr Weiguo Su | &nbsp;&nbsp;<br>Dr Weiguo Su |
| &nbsp;&nbsp;**2**  | &nbsp;&nbsp;**Reason for the notification**  | &nbsp;&nbsp;**Reason for the notification**  | &nbsp;&nbsp;**Reason for the notification**  |
| &nbsp;&nbsp;<br>a) | &nbsp;&nbsp;<br>Position/status<br>| &nbsp;&nbsp;<br>Executive Director, Chief Executive Officer and Chief Scientific Officer  | &nbsp;&nbsp;<br>Executive Director, Chief Executive Officer and Chief Scientific Officer  |
| &nbsp;&nbsp;<br>b) | &nbsp;&nbsp;<br>Initial notification/Amendment<br>| &nbsp;&nbsp;<br>Initial notification | &nbsp;&nbsp;<br>Initial notification |
| &nbsp;&nbsp;**3**  | &nbsp;&nbsp;**Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor**  | &nbsp;&nbsp;**Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor**  | &nbsp;&nbsp;**Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor**  |
| &nbsp;&nbsp;<br>a) | &nbsp;&nbsp;<br>Name<br>| &nbsp;&nbsp;<br>HUTCHMED (China) Limited | &nbsp;&nbsp;<br>HUTCHMED (China) Limited |
| &nbsp;&nbsp;<br>b) | &nbsp;&nbsp;<br>LEI<br>| &nbsp;&nbsp;<br>2138006X34YDQ6OBYE79 | &nbsp;&nbsp;<br>2138006X34YDQ6OBYE79 |
| &nbsp;&nbsp;**4**  | &nbsp;&nbsp;**Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted**  | &nbsp;&nbsp;**Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted**  | &nbsp;&nbsp;**Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted**  |
| &nbsp;&nbsp;<br>a) | &nbsp;&nbsp;<br>Description of the financial instrument, type of instrument<br>| &nbsp;&nbsp;<br>ADS each representing five Ordinary Shares of US$0.10 | &nbsp;&nbsp;<br>ADS each representing five Ordinary Shares of US$0.10 |
|  | &nbsp;&nbsp;Identification code<br>| &nbsp;&nbsp;ADS ISIN: US44842L1035 | &nbsp;&nbsp;ADS ISIN: US44842L1035 |
| &nbsp;&nbsp;<br>b) | &nbsp;&nbsp;<br>Nature of the transaction | &nbsp;&nbsp;<br>Vesting of awards granted on April 20, 2020 under HUTCHMED's LTIP | &nbsp;&nbsp;<br>Vesting of awards granted on April 20, 2020 under HUTCHMED's LTIP |
| &nbsp;&nbsp;<br>c) | &nbsp;&nbsp;<br>Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;<br>c) | &nbsp;&nbsp;<br>Price(s) and volume(s) | &nbsp;&nbsp;**Price(s)** | &nbsp;&nbsp;**Volume(s)** |
| &nbsp;&nbsp;<br>c) | &nbsp;&nbsp;<br>Price(s) and volume(s) | &nbsp;&nbsp;Nil | &nbsp;&nbsp;50,431 ADS |
| &nbsp;&nbsp;<br>c) | &nbsp;&nbsp;<br>Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;<br>d) | &nbsp;&nbsp;<br>Aggregated information | &nbsp;&nbsp;<br>N/A  | &nbsp;&nbsp;<br>N/A  |
| &nbsp;&nbsp;<br>d) | &nbsp;&nbsp;— Aggregated volume | &nbsp;&nbsp;<br>N/A  | &nbsp;&nbsp;<br>N/A  |
| &nbsp;&nbsp;<br>d) | &nbsp;&nbsp;— Price<br>| &nbsp;&nbsp;<br>N/A  | &nbsp;&nbsp;<br>N/A  |
| &nbsp;&nbsp;<br>e) | &nbsp;&nbsp;<br>Date of the transaction<br>| &nbsp;&nbsp;<br>2023-03-03 | &nbsp;&nbsp;<br>2023-03-03 |
| &nbsp;&nbsp;<br>f) | &nbsp;&nbsp;<br>Place of the transaction<br>| &nbsp;&nbsp;<br>Outside a trading venue | &nbsp;&nbsp;<br>Outside a trading venue |

---

------

&nbsp;&nbsp;&nbsp;&nbsp;**(b)** **Mr Johnny Cheng** 

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;<br>HIDDEN_ROW<br>|  |  |  |
| &nbsp;&nbsp;**1**  | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated**  | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated**  | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated**  |
| &nbsp;&nbsp;<br>a) | &nbsp;&nbsp;<br>Name<br>| &nbsp;&nbsp;<br>Mr Johnny Cheng | &nbsp;&nbsp;<br>Mr Johnny Cheng |
| &nbsp;&nbsp;**2**  | &nbsp;&nbsp;**Reason for the notification**  | &nbsp;&nbsp;**Reason for the notification**  | &nbsp;&nbsp;**Reason for the notification**  |
| &nbsp;&nbsp;<br>a) | &nbsp;&nbsp;<br>Position/status<br>| &nbsp;&nbsp;<br>Executive Director and Chief Financial Officer | &nbsp;&nbsp;<br>Executive Director and Chief Financial Officer |
| &nbsp;&nbsp;<br>b) | &nbsp;&nbsp;<br>Initial notification/Amendment<br>| &nbsp;&nbsp;<br>Initial notification | &nbsp;&nbsp;<br>Initial notification |
| &nbsp;&nbsp;**3**  | &nbsp;&nbsp;**Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor**  | &nbsp;&nbsp;**Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor**  | &nbsp;&nbsp;**Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor**  |
| &nbsp;&nbsp;<br>a) | &nbsp;&nbsp;<br>Name<br>| &nbsp;&nbsp;<br>HUTCHMED (China) Limited | &nbsp;&nbsp;<br>HUTCHMED (China) Limited |
| &nbsp;&nbsp;<br>b) | &nbsp;&nbsp;<br>LEI<br>| &nbsp;&nbsp;<br>2138006X34YDQ6OBYE79 | &nbsp;&nbsp;<br>2138006X34YDQ6OBYE79 |
| &nbsp;&nbsp;**4**  | &nbsp;&nbsp;**Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted**  | &nbsp;&nbsp;**Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted**  | &nbsp;&nbsp;**Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted**  |
| &nbsp;&nbsp;<br>a) | &nbsp;&nbsp;<br>Description of the financial instrument, type of instrument<br>| &nbsp;&nbsp;<br>ADS each representing five Ordinary Shares of US$0.10 | &nbsp;&nbsp;<br>ADS each representing five Ordinary Shares of US$0.10 |
|  | &nbsp;&nbsp;Identification code<br>| &nbsp;&nbsp;ADS ISIN: US44842L1035 | &nbsp;&nbsp;ADS ISIN: US44842L1035 |
| &nbsp;&nbsp;<br>b) | &nbsp;&nbsp;<br>Nature of the transaction | &nbsp;&nbsp;<br>Vesting of awards granted on April 20, 2020 under HUTCHMED's LTIP | &nbsp;&nbsp;<br>Vesting of awards granted on April 20, 2020 under HUTCHMED's LTIP |
| &nbsp;&nbsp;<br>c) | &nbsp;&nbsp;<br>Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;<br>c) | &nbsp;&nbsp;<br>Price(s) and volume(s) | &nbsp;&nbsp;**Price(s)** | &nbsp;&nbsp;**Volume(s)** |
| &nbsp;&nbsp;<br>c) | &nbsp;&nbsp;<br>Price(s) and volume(s) | &nbsp;&nbsp;Nil | &nbsp;&nbsp;22,953 ADS |
| &nbsp;&nbsp;<br>c) | &nbsp;&nbsp;<br>Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;<br>d) | &nbsp;&nbsp;<br>Aggregated information | &nbsp;&nbsp;<br>N/A  | &nbsp;&nbsp;<br>N/A  |
| &nbsp;&nbsp;<br>d) | &nbsp;&nbsp;— Aggregated volume | &nbsp;&nbsp;<br>N/A  | &nbsp;&nbsp;<br>N/A  |
| &nbsp;&nbsp;<br>d) | &nbsp;&nbsp;— Price<br>| &nbsp;&nbsp;<br>N/A  | &nbsp;&nbsp;<br>N/A  |
| &nbsp;&nbsp;<br>e) | &nbsp;&nbsp;<br>Date of the transaction<br>| &nbsp;&nbsp;<br>2023-03-03 | &nbsp;&nbsp;<br>2023-03-03 |
| &nbsp;&nbsp;<br>f) | &nbsp;&nbsp;<br>Place of the transaction<br>| &nbsp;&nbsp;<br>Outside a trading venue | &nbsp;&nbsp;<br>Outside a trading venue |

---

------

**About HUTCHMED**

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has about 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception HUTCHMED has been focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: <u>www.hutch-med.com</u> or follow us on <u>LinkedIn</u>.

**CONTACTS**

---

| | |
|:---|:---|
| **Investor Enquiries** |  |
| &nbsp;&nbsp;&nbsp;Mark Lee, Senior Vice President | +852 2121 8200 |
| &nbsp;&nbsp;&nbsp;Annie Cheng, Vice President | +1 (973) 306 4490 |
| **Media Enquiries** |  |
| &nbsp;&nbsp;&nbsp;**Americas** – Brad Miles, Solebury Trout | +1 (917) 570 7340 (Mobile) <br><u>bmiles@soleburystrat.com</u> |
| &nbsp;&nbsp;&nbsp;**Europe** – Ben Atwell / Alex Shaw, FTI Consulting | +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) <br><u>HUTCHMED@fticonsulting.com</u>  |
| &nbsp;&nbsp;&nbsp;**Asia** – Zhou Yi, Brunswick  | +852 9783 6894 (Mobile) <br><u>HUTCHMED@brunswickgroup.com</u> |
| **Nominated Advisor** |  |
| &nbsp;&nbsp;&nbsp;Atholl Tweedie / Freddy Crossley, <br>Panmure Gordon (UK) Limited | +44 (20) 7886 2500 |

---

------